On 15 June 2022 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation:
Recommendation No. 57/2022 of 15 June 2022 of the President of the Agency for Health Technology Assessment and Tariff System on the evaluation of Nplate (romiplostym) under the drug programme B.97. “Treatment of adult patients with primary immune thrombocytopenic purpura (ICD-10: D69.3)”